Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Transplantation
Volume 2017, Article ID 6290987, 5 pages
https://doi.org/10.1155/2017/6290987
Case Report

Immune Reconstitution Inflammatory Syndrome Occurring in a Kidney Transplant Patient with Extrapulmonary Tuberculosis

1Department of Nephrology, Jersey Shore University Medical Center, Neptune, NJ 07753, USA
2Rowan University School of Osteopathic Medicine, Stratford, NJ 08084, USA
3American University of Antigua College of Medicine, Coolidge, Antigua and Barbuda
4Ocean Renal Associates, 210 Jack Martin Boulevard, Brick, NJ 08724, USA

Correspondence should be addressed to Jose Iglesias; moc.liamg@32saiselgij

Received 7 November 2016; Accepted 22 February 2017; Published 7 March 2017

Academic Editor: Binnaz Handan Ozdemir

Copyright © 2017 Jose Iglesias et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Aguado, J. A. Herrero, J. Gavaldá et al., “Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain,” Transplantation, vol. 63, no. 9, pp. 1278–1286, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Singh and D. L. Paterson, “Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management,” Clinical Infectious Diseases, vol. 27, no. 5, pp. 1266–1277, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Torre-Cisneros, A. Doblas, J. M. Aguado et al., “Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the resitra (spanish network of infection in transplantation) cohort,” Clinical Infectious Diseases, vol. 48, no. 12, pp. 1657–1665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Muñoz, C. Rodríguez, and E. Bouza, “Mycobacterium tuberculosis infection in recipients of solid organ transplants,” Clinical Infectious Diseases, vol. 40, no. 4, pp. 581–587, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-E. C. Holty and R. R. Sista, “Mycobacterium tuberculosis infection in transplant recipients: early diagnosis and treatment of resistant tuberculosis,” Current Opinion in Organ Transplantation, vol. 14, no. 6, pp. 613–618, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Aguado, J. Torre-Cisneros, J. Fortun et al., “Tuberculosis in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in transplant recipients (GESITRA) of the Spanish society of infectious diseases and clinical microbiology,” Clinical Infectious Diseases, vol. 48, no. 9, pp. 1276–1284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J.-E. C. Holty, M. K. Gould, L. Meinke, E. B. Keeffe, and S. J. Ruoss, “Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data,” Liver Transplantation, vol. 15, no. 8, pp. 894–906, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. V. C. C. Cheng, P. L. Ho, R. A. Lee et al., “Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 21, no. 11, pp. 803–809, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. H.-Y. Sun and N. Singh, “Opportunistic infection-associated immune reconstitution syndrome in transplant recipients,” Clinical Infectious Diseases, vol. 53, no. 2, pp. 168–176, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. H.-Y. Sun, P. Munoz, J. Torre-Cisneros et al., “Mycobacterium tuberculosis—associated immune reconstitution syndrome in solid-organ transplant recipients,” Transplantation, vol. 95, no. 9, pp. 1173–1181, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. B. T. Ngo, M. Pascoe, and D. Khan, “Drug interaction between rifampicin and sirolimus in transplant patients,” Saudi Journal of Kidney Diseases and Transplantation, vol. 22, no. 1, pp. 112–115, 2011. View at Google Scholar · View at Scopus
  12. A. M. Baciewicz, C. R. Chrisman, C. K. Finch, and T. H. Self, “Update on rifampin, rifabutin, and rifapentine drug interactions,” Current Medical Research and Opinion, vol. 29, no. 1, pp. 1–12, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. D. R. J. Kuypers, G. Verleden, M. Naesens, and Y. Vanrenterghem, “Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase,” Clinical Pharmacology and Therapeutics, vol. 78, no. 1, pp. 81–88, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Place, C. Knoop, M. Remmelink et al., “Paradoxical worsening of tuberculosis in a heart-lung transplant recipient,” Transplant Infectious Disease, vol. 9, no. 3, pp. 219–224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Asano, H. Kawamoto, J. Asakuma, T. Tanimoto, H. Kobayashi, and M. Hayakawa, “Paradoxical worsening of tuberculosis after anti-TB therapy in a kidney transplant recipient,” Transplantation Proceedings, vol. 32, no. 7, pp. 1960–1962, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Mohapatra, G. Basu, I. Sen et al., “Tuberculosis in a renal allograft recipient presenting with intussusception,” Indian Journal of Nephrology, vol. 22, no. 1, pp. 52–56, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. X. Chen, B. Zhou, M. Li et al., “CD4+CD25+FoxP3+ regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease,” Clinical Immunology, vol. 123, no. 1, pp. 50–59, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. K. M. Quinn, R. S. McHugh, F. J. Rich et al., “Inactivation of CD4+CD25+ regulatory T cells during early mycobacterial infection increases cytokine production but does not affect pathogen load,” Immunology and Cell Biology, vol. 84, no. 5, pp. 467–474, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Demirkiran, T. K. Hendrikx, C. C. Baan, and L. J. W. Van Der Laan, “Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to the clinical setting?” Transplantation, vol. 85, no. 6, pp. 783–789, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Arias-Diaz, J. A. Ildefonso, J. J. Muñoz, A. Zapata, and E. Jiménez, “Both tacrolimus and sirolimus decrease Th1/Th2 ratio, and increase regulatory T lymphocytes in the liver after ischemia/reperfusion,” Laboratory Investigation, vol. 89, no. 4, pp. 433–445, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Havari, M. J. Turner, J. Campos-Rivera et al., “Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro,” Immunology, vol. 141, no. 1, pp. 123–131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. Center for Disease Control and Prevention: Tuberculosis (TB) Data and Statistics, CDC, 2016, https://www.cdc.gov/tb/statistics/.
  23. H. M. Peto, R. H. Pratt, T. A. Harrington, P. A. LoBue, and L. R. Armstrong, “Epidemiology of extrapulmonary tuberculosis in the United States, 1993–2006,” Clinical Infectious Diseases, vol. 49, no. 9, pp. 1350–1357, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Scott, H. L. Kirking, C. Jeffries, S. F. Price, and R. Pratt, “Tuberculosis trends—United States, 2014,” Morbidity and Mortality Weekly Report, vol. 64, no. 10, pp. 265–269, 2015. View at Google Scholar · View at Scopus
  25. C. C. Dobler, S. P. McDonald, and G. B. Marks, “Risk of tuberculosis in dialysis patients: a nationwide cohort study,” PLoS ONE, vol. 6, no. 12, Article ID e29563, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. W.-Y. Au, A. Y. H. Leung, E. W. C. Tse, W. W. W. Cheung, T. W. H. Shek, and Y.-L. Kwong, “High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients,” Leukemia Research, vol. 32, no. 4, pp. 547–551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. I. Martin, F. M. Marty, K. Fiumara, S. P. Treon, J. G. Gribben, and L. R. Baden, “Infectious complications associated with alemtuzumab use for lymphoproliferative disorders,” Clinical Infectious Diseases, vol. 43, no. 1, pp. 16–24, 2006. View at Publisher · View at Google Scholar · View at Scopus